Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Decreases By 7.9%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTGet Rating) saw a large drop in short interest in December. As of December 30th, there was short interest totalling 39,400 shares, a drop of 7.9% from the December 15th total of 42,800 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average trading volume of 31,900 shares, the short-interest ratio is presently 1.2 days.

Insider Activity

In related news, Director Rene Bernards acquired 52,500 shares of the firm’s stock in a transaction dated Monday, November 14th. The stock was bought at an average price of $0.53 per share, for a total transaction of $27,825.00. Following the acquisition, the director now directly owns 125,000 shares of the company’s stock, valued at $66,250. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased 88,809 shares of company stock worth $47,911 in the last quarter. Corporate insiders own 29.20% of the company’s stock.

Institutional Investors Weigh In On Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. EP Wealth Advisors LLC bought a new stake in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTGet Rating) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,025 shares of the company’s stock, valued at approximately $31,000. EP Wealth Advisors LLC owned about 0.15% of Lixte Biotechnology as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 3.90% of the company’s stock.

Lixte Biotechnology Price Performance

Shares of NASDAQ LIXT opened at $0.71 on Monday. The stock has a market capitalization of $11.82 million, a price-to-earnings ratio of -1.54 and a beta of -0.50. The business has a 50-day moving average of $0.58 and a 200-day moving average of $0.64. Lixte Biotechnology has a fifty-two week low of $0.43 and a fifty-two week high of $4.95.

Lixte Biotechnology (NASDAQ:LIXTGet Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.09) earnings per share (EPS) for the quarter.

About Lixte Biotechnology

(Get Rating)

Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.

Read More

Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.